

NON-PREFERRED ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)

Applies To:

candesartan (ATACAND)
candesartan cilexetil-hydrochlorothiazide (ATACAND HCT)
azilsartan (EDARBI)
azilsartan-chlorthalidone (EDARBYCLOR)
eprosartan 600mg
olmesartan-amlodipine-hydrochlorothiazide (TRIBENZOR)
telmisartan-amlodipine (TWYNSTA)
telmisartan-hydrochlorothiazide (MICARDIS HCT)

Diagnoses Considered for Coverage:

- Hypertension (HTN)
- Chronic Heart Failure (CHF)
- Diabetic Nephropathy
- Migraine prophylaxis – *candesartan only*

Coverage Criteria:

For all diagnoses above:

- Dose does not exceed FDA label maximum, **and**
- Meets step therapy requirement in table below:

DRUG	STEP THERAPY
candesartan (Atacand) candesartan-HCTZ (Atacand HCT) eprosartan 600 mg telmisartan-amlodipine (Twynsta) telmisartan-HCTZ (Micardis HCT) olmesartan-amlodipine-HCTZ (Tribenzor) Edarbi Edarbyclor	Inadequate response or intolerable side effect to TWO formulary ARBs including: • irbesartan (Avapro) • irbesartan-HCTZ (Avalide) • losartan (Cozaar) • losartan-HCTZ (Hyzaar) • olmesartan-amlodipine (Azor) • olmesartan (Benicar) • olmesartan-HCTZ (Benicar HCT) • telmisartan (Micardis) • valsartan (Diovan) • valsartan-HCTZ (Diovan HCT) • valsartan-amlodipine (Exforge) • valsartan-amlodipine-hctz (Exforge HCT)

Coverage Duration: one year

Effective Date: 1/3/2024